Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 11/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009327 | 0.92 | SLC6A9 (0.64) | TSHRCTSSCTSKSLC6A9SLC6A5 | |
| SCHEMBL15145801 | 0.87 | GPR139 (0.62) | CTSKGPR139MEN1KMT2A | |
| SCHEMBL16265379 | 0.87 | GPR139 (0.62) | CTSKGPR139MEN1KMT2A | |
| SCHEMBL7369435 | 0.87 | CTSK (0.52) | TSHRCTSSCTSKSLC6A9SLC6A5 | |
| SCHEMBL18989452 | 0.86 | CTSK (0.50) | CTSSCTSKSYKGPR139MAPT | |
| SCHEMBL18989457 | 0.86 | CTSK (0.50) | CTSSCTSKSYKGPR139MAPT | |
| SCHEMBL18989598 | 0.86 | CTSK (0.50) | CTSSCTSKSYKGPR139MAPT | |
| SCHEMBL7408909 | 0.86 | CTSS (0.57) | CTSSCTSK | |
| SCHEMBL7371036 | 0.85 | CTSS (0.55) | TSHRCTSSCTSKSLC6A9SLC6A5 | |
| SCHEMBL23332653 | 0.85 | CTSK (0.55) | CTSSCTSKSYKGPR139MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6065287-A | — | — | None | — | — | JP | disclosed |
| US-8722919-B2 | Process for production of mono-substituted alkylated compound using aldimine or derivative thereof | NAGASE & CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8722919-B2 | Process for production of mono-substituted alkylated compound using aldimine or derivative thereof | NAGASE & CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20090054679-A1 | PROCESS FOR PRODUCTION OF MONO-SUBSTITUTED ALKYLATED COMPOUND USING ALDIMINE OR DERIVATIVE THEREOF | NAGASE & CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090054679-A1 | PROCESS FOR PRODUCTION OF MONO-SUBSTITUTED ALKYLATED COMPOUND USING ALDIMINE OR DERIVATIVE THEREOF | NAGASE & CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| JP-H0665287-A | PEPTIDE | NISSHIN FLOUR MILLING CO LTD | 1994-03-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054679-A1 | PROCESS FOR PRODUCTION OF MONO-SUBSTITUTED ALKYLATED COMPOUND USING ALDIMINE OR DERIVATIVE THEREOF | AADAT, BCAT2, BCAT1 | TSHR 4219/4885CTSS 4733/4885CTSK 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.